CA2992420A1 - Method for the reduction of host cell proteins in affinity chromatography - Google Patents

Method for the reduction of host cell proteins in affinity chromatography Download PDF

Info

Publication number
CA2992420A1
CA2992420A1 CA2992420A CA2992420A CA2992420A1 CA 2992420 A1 CA2992420 A1 CA 2992420A1 CA 2992420 A CA2992420 A CA 2992420A CA 2992420 A CA2992420 A CA 2992420A CA 2992420 A1 CA2992420 A1 CA 2992420A1
Authority
CA
Canada
Prior art keywords
antibody
aqueous solution
antibody against
protein
conductivity aqueous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2992420A
Other languages
English (en)
French (fr)
Inventor
Paul Mcdonald
Richard St. John
Marc WONG
Roberto Falkenstein
Wolfgang Koehnlein
Klaus Schwendner
Bernhard SPENSBERGER
Michael Wiedmann
Frank Zettl
Annika KLEINJANS
Carina KOPP
Benjamin TRAN
Ryan Erickson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Genentech Inc
Original Assignee
F Hoffmann La Roche AG
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56802471&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2992420(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F Hoffmann La Roche AG, Genentech Inc filed Critical F Hoffmann La Roche AG
Publication of CA2992420A1 publication Critical patent/CA2992420A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3007—Carcino-embryonic Antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Analytical Chemistry (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Treatment Of Liquids With Adsorbents In General (AREA)
CA2992420A 2015-08-21 2016-08-18 Method for the reduction of host cell proteins in affinity chromatography Pending CA2992420A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562208523P 2015-08-21 2015-08-21
US62/208,523 2015-08-21
PCT/EP2016/069604 WO2017032686A1 (en) 2015-08-21 2016-08-18 Method for the reduction of host cell proteins in affinity chromatography

Publications (1)

Publication Number Publication Date
CA2992420A1 true CA2992420A1 (en) 2017-03-02

Family

ID=56802471

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2992420A Pending CA2992420A1 (en) 2015-08-21 2016-08-18 Method for the reduction of host cell proteins in affinity chromatography

Country Status (14)

Country Link
US (3) US20180186832A1 (https=)
EP (1) EP3337812B1 (https=)
JP (4) JP6968055B2 (https=)
KR (2) KR102691585B1 (https=)
CN (2) CN107849087B (https=)
AU (1) AU2016312909B2 (https=)
CA (1) CA2992420A1 (https=)
ES (1) ES2877532T3 (https=)
HR (1) HRP20211026T1 (https=)
IL (1) IL257146B2 (https=)
MX (1) MX388197B (https=)
PL (1) PL3337812T3 (https=)
SI (1) SI3337812T1 (https=)
WO (1) WO2017032686A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2017003116A (es) 2014-09-10 2017-05-23 Procter & Gamble Trama de tela no tejida.
HRP20211737T1 (hr) 2015-08-21 2022-02-18 F. Hoffmann - La Roche Ag Postupak za smanjenje proteina stanice domaćina u afinitetnoj kromatografiji
EP3337818B1 (en) * 2015-08-21 2026-03-18 F. Hoffmann-La Roche AG Affinity chromatography purification with low conductivity wash buffer
SI3337812T1 (sl) 2015-08-21 2021-08-31 F. Hoffmann-La Roche Ag Postopek za zmanjševanje beljakovin gostiteljske celice v afinitetni kromatografiji
EP3788150A4 (en) * 2018-05-04 2022-01-26 Sigma-Aldrich Co. LLC PRODUCTION OF RECOMBINANT PROTEINS WITH REDUCED LEVELS OF HOST CELL PROTEINS
EP3826743A4 (en) * 2018-07-25 2022-09-14 Merck Sharp & Dohme Corp. METHODS FOR SEPARATION OF HOST CELL LIPASES FROM A PRODUCTION PROTEIN IN CHROMATOGRAPHIC METHODS
WO2020153390A1 (ja) * 2019-01-23 2020-07-30 第一三共株式会社 活性炭材料を使用する工程を含む抗体精製方法
JP2023500775A (ja) * 2019-09-23 2023-01-11 メルク・シャープ・アンド・ドーム・エルエルシー 宿主細胞タンパク質が減少し、ポリソルベート－８０安定性が増加した、抗ｃｔｌａ４モノクローナル抗体を含む方法および組成物
WO2023284073A1 (zh) * 2021-07-13 2023-01-19 江苏荃信生物医药股份有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂
US20250223313A1 (en) * 2022-01-14 2025-07-10 Shattuck Labs, Inc. Methods of contaminant removal from protein isolates
WO2024178239A1 (en) * 2023-02-22 2024-08-29 Shattuck Labs, Inc. Engineered cell lines and uses thereof

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
DE69738075T2 (de) 1996-11-27 2008-05-21 Genentech, Inc., South San Francisco Affinitätsreinigung von polypeptiden an einer protein a-matrix
DE1257584T1 (de) 2000-02-24 2003-05-28 Lilly Co Eli Humanisierte antikörper, die amyloid beta peptid demarkieren
WO2002072615A1 (en) 2001-03-09 2002-09-19 Chugai Seiyaku Kabushiki Kaisha Method of purifying protein
TWI338009B (en) 2001-10-29 2011-03-01 Genentech Inc Antibodies for inhibiting blood coagulation and methods of use thereof
AR038568A1 (es) 2002-02-20 2005-01-19 Hoffmann La Roche Anticuerpos anti-a beta y su uso
EP3225625A1 (en) 2002-09-11 2017-10-04 Chugai Seiyaku Kabushiki Kaisha Protein purification method
ATE468886T1 (de) 2003-02-10 2010-06-15 Applied Molecular Evolution Abeta-bindende moleküle
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
CA2581208A1 (en) 2004-08-30 2006-03-09 Lonza Biologics Plc. Affinity- plus ion exchange- chromatography for purifying antibodies
TWI306862B (en) 2005-01-03 2009-03-01 Hoffmann La Roche Antibodies against il-13 receptor alpha 1 and uses thereof
PT1876236E (pt) 2005-04-08 2014-10-22 Chugai Pharmaceutical Co Ltd Anticorpos para substituição da função do factor de coagulação sanguínea viii
ZA200710330B (en) 2005-06-17 2009-12-30 Wyeth Corp Methods of purifying FC region containing proteins
MY155286A (en) * 2005-12-12 2015-09-30 Hoffmann La Roche Antibodies against amyloid beta 4 with glycosylated in the variable region
WO2007109163A2 (en) 2006-03-16 2007-09-27 Amgen Inc Wash buffer and method of using
EP2046833B9 (en) 2006-07-14 2014-02-19 AC Immune S.A. Humanized antibody against amyloid beta
RU2474585C2 (ru) 2007-01-22 2013-02-10 Дженентек, Инк. Осаждение и очистка белков полиэлектролитами
EP2278999B1 (en) * 2008-04-21 2025-01-29 Dompé farmaceutici S.p.A. Auris formulations for treating otic diseases and conditions
RU2474588C2 (ru) 2008-05-05 2013-02-10 Новиммун Са Перекрестно-реактивные антитела анти-il-17a/il-17f и способы их применения
EP2116556B1 (en) 2008-05-09 2016-03-23 AbbVie Deutschland GmbH & Co KG Antibodies to receptor of advanced glycation end products (RAGE) and uses thereof
BRPI0919879A2 (pt) 2008-10-29 2016-02-16 Wyeth Llc métodos para purificação de moléculas de ligação a antígeno de domínio único
WO2011038894A1 (en) * 2009-10-01 2011-04-07 F. Hoffmann-La Roche Ag Protein a chromatography
ES2982297T3 (es) 2009-12-18 2024-10-15 Novartis Ag Método de cromatografía de afinidad
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
KR101860963B1 (ko) 2010-04-23 2018-05-24 제넨테크, 인크. 이종다량체 단백질의 생산
EP2583973B1 (en) 2010-06-21 2018-03-21 Kyowa Hakko Kirin Co., Ltd. Method for purifying protein using amino acid
WO2012047732A2 (en) 2010-09-29 2012-04-12 Genentech, Inc. Antibody compositions and methods of use
TWI452136B (zh) 2010-11-17 2014-09-11 中外製藥股份有限公司 A multiple specific antigen-binding molecule that replaces the function of Factor VIII in blood coagulation
EP2714714B1 (en) 2011-06-01 2018-06-20 Novartis AG Wash solution and method for affinity chromatography
WO2013033517A1 (en) 2011-09-01 2013-03-07 Human Genome Sciences, Inc. Viral clearance methods
HUE035685T2 (en) 2011-11-02 2018-05-28 Hoffmann La Roche Overload and elute chromatography
EP2849723B1 (en) * 2012-05-18 2018-05-02 Genentech, Inc. High-concentration monoclonal antibody formulations
TW201348247A (zh) 2012-05-21 2013-12-01 Abbvie Inc 利用蛋白質ａ親和性層析之非人類抗體之新穎純化
UA118028C2 (uk) 2013-04-03 2018-11-12 Рош Глікарт Аг Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
EP2997036B1 (en) 2013-05-15 2021-03-03 Medimmune Limited Purification of recombinantly produced polypeptides
TWI596107B (zh) * 2013-06-25 2017-08-21 卡地拉保健有限公司 單株抗體之新穎純化方法
US10144774B2 (en) * 2013-07-01 2018-12-04 Csl Behring Ag Method for purifying IgG
CN105473612A (zh) * 2013-08-19 2016-04-06 豪夫迈·罗氏有限公司 用羟基磷灰石层析分离双特异性抗体和双特异性抗体生产副产物
CN120904322A (zh) * 2013-09-13 2025-11-07 豪夫迈·罗氏有限公司 包含纯化的重组多肽的方法和组合物
JPWO2015041218A1 (ja) 2013-09-17 2017-03-02 株式会社カネカ 新規抗体精製方法及びそれから得られる抗体（ＮｏｖｅｌＡｎｔｉｂｏｄｙＰｕｒｉｆｉｃａｔｉｏｎＭｅｔｈｏｄａｎｄＡｎｔｉｂｏｄｙｏｂｔａｉｎｅｄｔｈｅｒｅｆｒｏｍ）、並びに陽イオン交換基を用いた新規抗体精製法及びそれから得られる抗体（ＮｏｖｅｌＡｎｔｉｂｏｄｙＰｕｒｉｆｉｃａｔｉｏｎｍｅｔｈｏｄｕｓｉｎｇＣａｔｉｏｎＥｘｃｈａｎｇｅｒａｎｄＡｎｔｉｂｏｄｙｏｂｔａｉｎｅｄｔｈｅｒｅｆｒｏｍ）
JP2015083558A (ja) 2013-09-18 2015-04-30 東ソー株式会社 抗体吸着剤ならびにそれを用いた抗体の精製方法および識別方法
CN103497248B (zh) * 2013-09-22 2016-08-10 中国抗体制药有限公司 一种从细胞培养上清中分离纯化抗体的方法
US20160286398A1 (en) 2015-03-23 2016-09-29 Qualcomm Incorporated Schedule selection and connection setup between devices participating in a nan data link
HRP20211737T1 (hr) 2015-08-21 2022-02-18 F. Hoffmann - La Roche Ag Postupak za smanjenje proteina stanice domaćina u afinitetnoj kromatografiji
EP3337818B1 (en) 2015-08-21 2026-03-18 F. Hoffmann-La Roche AG Affinity chromatography purification with low conductivity wash buffer
SI3337812T1 (sl) 2015-08-21 2021-08-31 F. Hoffmann-La Roche Ag Postopek za zmanjševanje beljakovin gostiteljske celice v afinitetni kromatografiji
JP2021124951A (ja) 2020-02-05 2021-08-30 富士通株式会社 情報処理システム、情報処理装置およびアクセス制御方法

Also Published As

Publication number Publication date
MX388197B (es) 2025-03-19
JP6968055B2 (ja) 2021-11-17
ES2877532T3 (es) 2021-11-17
IL257146A (en) 2018-03-29
EP3337812A1 (en) 2018-06-27
JP7610638B2 (ja) 2025-01-08
KR20240121902A (ko) 2024-08-09
CN116063375A (zh) 2023-05-05
AU2016312909A1 (en) 2018-02-22
AU2016312909B2 (en) 2022-12-08
MX2018001536A (es) 2018-04-24
WO2017032686A1 (en) 2017-03-02
JP2021176900A (ja) 2021-11-11
EP3337812B1 (en) 2021-04-28
JP7258964B2 (ja) 2023-04-17
JP2023076617A (ja) 2023-06-01
IL257146B1 (en) 2024-09-01
US20260085090A1 (en) 2026-03-26
CN107849087A (zh) 2018-03-27
CN107849087B (zh) 2022-09-06
US20220169675A1 (en) 2022-06-02
KR20180034500A (ko) 2018-04-04
KR102691585B1 (ko) 2024-08-05
JP2025031829A (ja) 2025-03-07
HRP20211026T1 (hr) 2021-10-01
HK1251584A1 (zh) 2019-02-01
IL257146B2 (en) 2025-01-01
US20180186832A1 (en) 2018-07-05
SI3337812T1 (sl) 2021-08-31
BR112018001511A2 (pt) 2018-09-18
JP2018531895A (ja) 2018-11-01
US12503487B2 (en) 2025-12-23
PL3337812T3 (pl) 2021-10-11

Similar Documents

Publication Publication Date Title
US12503487B2 (en) Method for the reduction of host cell proteins in affinity chromatography
JP7084301B2 (ja) 低伝導率洗浄緩衝液を用いたアフィニティークロマトグラフィー精製方法
US20220119499A1 (en) Method for the reduction of host cell proteins in affinity chromatography
HK40090146A (zh) 在亲和层析中减少宿主细胞蛋白的方法
HK1251584B (en) Method for the reduction of host cell proteins in affinity chromatography
BR112018001511B1 (pt) Uso de solução aquosa com baixa condutividade e métodos de produção e purificação de anticorpos de isotipo igg1 ou igg4 humano
HK1249122B (zh) 用低电导率洗涤缓冲液进行亲和层析纯化

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20210804

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20240726

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D149 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S INTERVIEW

Effective date: 20240823

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT

Effective date: 20240916

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241217

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241217

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241218

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250305

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250305

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NOTICE OF ALLOWANCE IS ISSUED

Effective date: 20250609

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250609

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250609

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250724

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250724

D00 Search and/or examination requested or commenced

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D00-D164 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: RESPONSE TO NOTICE OF ALLOWANCE

Effective date: 20251006

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-2-4-D10-D22-D143 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRE-GRANT

Effective date: 20260312

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260312